Capital Impact Advisors’s Genomic Health, Inc. GHDX Stock Holding History

Capital Impact Advisors’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-28,570	Closed	-$1.96M	–	124
2019 Q3	$1.96M	Sell	28,570 -7,372	-21%	-$506K	0.75%	66
2019 Q2	$2.02M	Buy	35,942 +11,277	+46%	+$668K	0.74%	48
2019 Q1	$1.57M	Hold	24,665	–	–	0.7%	74
2018 Q4	$1.57M	Sell	24,665 -9,794	-28%	-$687K	0.67%	77
2018 Q3	$2.39M	Sell	34,459 -1,834	-5%	-$107K	0.82%	39
2018 Q2	$1.81M	Buy	+36,293	New	+$1.44M	0.67%	67

Capital Impact Advisors's GHDX Position: Q4 2019 in Review

Capital Impact Advisors sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 28,570 shares — an estimated $1.96M sold.

Capital Impact Advisors first reported a position in GHDX in Q2 2018 and held it in 6 quarters. The position peaked at $2.39M in Q3 2018. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.

Capital Impact Advisors reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
Capital Impact Advisors sold 28,570 Genomic Health, Inc. shares in Q4 2019, an estimated $1.96M.
Capital Impact Advisors first reported a position in Genomic Health, Inc. in Q2 2018 and held it in 6 quarters.
Capital Impact Advisors's Genomic Health, Inc. position peaked at $2.39M in Q3 2018.
0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.

Based on Capital Impact Advisors's 13F filing for Q4 2019, filed 13 Feb 2020.